- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04610476
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
A Prospective, Randomized, Controlled, Open Label, Assessor-blinded, Parallel-group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy in a Treat-to-target Approach on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: David Simon, MD
- Phone Number: +4991318532093
- Email: david.simon@uk-erlangen.de
Study Contact Backup
- Name: Arnd Kleyer, MD
- Phone Number: +4991318532093
- Email: arnd.kleyer@uk-erlangen.de
Study Locations
-
-
Bavaria
-
Erlangen, Bavaria, Germany, 91054
- Recruiting
- Universitatsklinikum Erlangen
-
Contact:
- David Simon, MD
- Phone Number: +4991318532093
- Email: david.simon@uk-erlangen.de
-
Contact:
- Arnd Kleyer, MD
- Phone Number: +4991318532093
- Email: arnd.kleyer@uk-erlangen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent obtained from the subject
- Understanding of study procedures and willingness to abide by all procedures during the course of the study.
- Adult subject; age range 18-≤75 years
- Male or female subject
- Diagnosis of PsA according to CASPAR criteria
- Disease status "MDA" for at least 6 months
Subject should have been treated without alterations of therapy (fixed dose and drug) for at least 6 months with one or more of the following drugs:
i. csDMARD Leflunomid (e.g. Arava), Sulfasalazin (e.g. Azulfidine RA, Pleon RA), Methotrexate (e.g. Lantarel, Metex) AND/OR ii. bDMARD/tsDMARD: Etanercept (e.g. Enbrel, Erelzi, Benepali), Adalimumab (e.g. Humira, Amgevita, Imraldi, Hyrimoz), Infliximab (e.g. Remicade, Zessly, Inflectra), Golimumab (Simponi), Certolizumab (Cimzia), Abatacept (Orencia), Apremilast (Otezla), Ustekinumab (Stelara), Secukinumab (Cosentyx), Ixekizumab (Taltz), Tofacitinib (Xeljanz) AND/OR (c) glucocorticoids (≤5mg prednisolone equivalent).
- Women of childbearing potential must be using a highly effective method of birth control.
- Male subjects using an adequate contraceptive method at the investigator's discretion.
Exclusion Criteria:
- Diagnosis of any other rheumatological/ immunological disease such as rheumatoid arthritis, SLE, PSS, MCTD, M. Behcet or M. Wegener
- Concomitant florid (not sufficiently adjusted under treatment) autoimmune disease such as autoimmune hepatitis or Hashimoto's disease
- Use of any inadmissible medication (e.g. current treatment with DMARDs other than mentioned above or drugs under development)
- Treatment with systemic glucocorticoids (daily dose >5mg prednisolone equivalent) during the last 6 months before randomization. Intra-articular or entheseal injections of glucocorticoids do not constitute an exclusion criterion
- Malignant disease currently under oncological treatment or history of a recent malignancy with moderate or high risk of relapse within 5 years prior to Screening
- Existence of another disease including the presence of laboratory abnormalities which, at the discretion of the investigator, would result in a disproportionate risk to the patient concerned or confounds the ability to interpret data from the study
- Any anti-inflammatory (excluding NSAIDs) or immunosuppressive therapy for other reasons than PsA or psoriasis during the last 3 months before Screening
- Nursing mother or pregnant woman as verified by a positive pregnancy test
- Known hypersensitivity to the IMPs or any of their formulation ingredients
- Subject who is imprisoned or is lawfully kept in an Institution
- Employee or direct relative of an employee of the study site or the Sponsor
- Participation in an interventional clinical study with an IMP within the last 4 weeks before Screening
- Previous participation in this clinical study
- Planned extended stay outside the region which prevents compliance with the visit schedule
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
Individual previous stable glucocorticoid/DMARD therapy is continued
|
|
Experimental: Reduction group
Individual previous stable dosage of glucocorticoids/DMARDs will be stepwise reduced according to a predefined algorithm
|
Prednisolone oral 1-5 mg/day
Other Names:
Sulfasalazine oral 2 x 1000 mg/day
Other Names:
Leflunomide oral 20 mg/day
Other Names:
Methotrexate oral > 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
Other Names:
Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day
Other Names:
Apremilast oral 2 x 30 mg/day/1 x 30 mg/day
Other Names:
Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week
Other Names:
Adalimumab s.c.
40 mg every 2 weeks
Other Names:
Infliximab i.v. 5 mg/kg BW every 8 weeks
Other Names:
Certolizumab pegol s.c.
1x 200 mg every 2 weeks/1x400 mg every 4 weeks
Other Names:
Golimumab s.c.
1x 50 mg every 4 weeks
Other Names:
Abatacept s.c.
1x125 mg/week OR Abatacept i.v.
500-1000mg (adapted to BW) every 4 weeks
Other Names:
Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
Other Names:
Ixekizumab s.c.
1x 80 mg every 4 weeks
Other Names:
Ustekinumab s.c.
Maintenance dose 1x45 mg every 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of MDA (minimal disease activity) 12 months after baseline.
Time Frame: 12 months
|
The MDA status comprises the assessment of different domains of PsA, consisting of the following individual components:
MDA is defined as the presence of 5 of the following 7 criteria:
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Key secondary endpoint: PASDAS (Psoriatic Arthritis Disease Activity Score)
Time Frame: 12 months
|
The PASDAS is a composite disease activity index (range 0-10) for psoriatic arthritis (PsA) incorporating seven domains: patient and physician global activity VAS scores, tender and swollen joint counts (arthritis), dactylitis, enthesitis (Leeds), health-related QoL (SF-36), and CRP level. PASDAS has demonstrated to have a better discriminate capacity in distinguishing high and low disease activity. The PASDAS is computed by the following equation: PASDAS = (((0, 18 ∗ ∗√(PhGA) + 0.159 ∗ ∗√(PtGA) - 0.253 ∗ ∗√(SF36 -PCS) + 0.101 ∗ lognat(SJC66 + 1)) + 0.048 ∗ lognat(SJC68 +1)) + 0.23 ∗ lognat (Leeds enthesitis index + 1)) + 0.37 ∗lognat (tender dactylitis count + 1) + 0.102 ∗ lognat (CRP +1) + 2 ∗ 1.5. |
12 months
|
Key secondary endpoint: DAPSA (Disease Activity in PSoriatic Arthritis)
Time Frame: 12 months
|
The DAPSA score determines changes in the disease activity of subjects diagnosed with PsA.
DAPSA is a composite score which is calculated from the sum of: number of tender joints (0-68), number of swollen joints (0-66, hips are not taken into account), CRP (mg/dl), subject's assessment of global status of disease activity using VAS (0-10) and patient's self-assessment of pain using VAS (0-10).
A value of the composite score DAPSA 0-≤ 4 marks remission, 5-14 marks low, 15-28 moderate and >28 high disease activity
|
12 months
|
Key secondary endpoint: CPDAI (Composite Psoriatic Disease Activity Index)
Time Frame: 12 months
|
The composite psoriatic disease activity index (CPDAI) assesses disease activity under five domains using well established and validated instruments of PsA disease documentation as proposed by GRAPPA.
The domains and the respective instrument are as follows: joint disease (SJC/TJC, HAQ), skin involvement (PASI, DLQI), enthesitis (LEI, HAQ), dactylitis (dactylitis digit count, HAQ) and spinal involvement (BASDAI and ASQoL).
Using the instruments and ranges of values, disease activity under each domain is graded as none (0) -mild (1) -moderate (2) and severe (3) giving a range attainable CPDAI scores of between 0 and 15.
The CPDAI correlates well with patient and physician global disease activity assessments and is an effective tool that clearly distinguishes those who require a treatment change from those who do not.
|
12 months
|
Number of swollen and tender joints
Time Frame: 12 months
|
An assessment of 66 joints for swelling and 68 joints for tenderness will be made (including the DIP joints of the hands and excluding hips for swelling).
|
12 months
|
Number of tender entheseal points: SPARCC (Spondyloarthritis Consortium of Canada)
Time Frame: 12 months
|
The SPARCC enthesitis score is based on the counting of the presence or absence of tenderness on 16 entheseal sites (eight sites on each body side, respectively): lateral epicondyle, medial epicondyle, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior borders of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle, Achilles tendon insertion into calcaneum, and plantar fascia insertion into calcaneum.
Tenderness on examination is recorded as either present (1) or absent (0) for each of the 16 sites, summarized in an overall score ranging from 0 to 16.
A higher count represents a greater enthesitis burden
|
12 months
|
Number of tender entheseal Points: LEI (Leeds Enthesitis Index)
Time Frame: 12 months
|
The LEI includes 3 entheseal sites on each body side, respectively: lateral epicondyles, medial condyles of the femur, and Achilles tendons.
Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 sites, for in an overall score ranging from 0 to 6.
A higher count represents a greater enthesitis burden
|
12 months
|
Number of tender entheseal Points: MASES (Maastricht Ankylosing Spondylitis Enthesitis Score)
Time Frame: 12 months
|
The MASES includes 6 entheseal sites on each body side (first costochondral joints, seventh costochondral joints, posterior superior iliac spines, anterior superior iliac spines, iliac crests, proximal insertion of Achilles tendons) and in addition the fifth lumbar spinous process.
Tenderness on examination is recorded as either present (1) or absent (0) for each of the 13 sites, for an overall score ranging from 0 to 13.
A higher count represents a greater enthesitis burden
|
12 months
|
Dactylitis counts
Time Frame: 12 months
|
The presence of dactylitis will be assessed by counting the fingers/toes with dactylitis.
|
12 months
|
Activity of psoriasis: PASI (Psoriasis Area and Severity Index)
Time Frame: 12 months
|
PASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 (no disease) to 72 (maximal disease).
|
12 months
|
Activity of psoriasis: BSA (body surface area)
Time Frame: 12 months
|
For the BSA assessment of psoriatic skin involvement the size of the subject's hand is used as a scale to estimate the size of the skin surface covered by psoriasis.
The subject's palm covers roughly 1% of body's surface area.
An involved area of <3% of the skin is considered as mild, of 3 10% as moderate, and >10% as severe psoriasis
|
12 months
|
Activity of axial Involvement: BASDAI (Disease Activity of Ankylosing Spondylitis)
Time Frame: 12 months
|
The BASDAI consists of a one through 10 scale (one being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of AS: Fatigue, Spinal pain, Joint pain / swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity. To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score. Scores of 4 or greater suggest suboptimal control of disease, and patients with scores of 4 or greater are usually good candidates for either a change in their medical therapy or for enrollment in clinical trials evaluating new drug therapies directed at Ankylosing Spondylitis |
12 months
|
Quality of life and health/disability: PsAID-12 (Psoriatic Arthritis Impact of Disease)
Time Frame: 12 months
|
The PsAID-12 is a score based on a subject's self-assessment questionnaire and used to measure the impact of psoriatic arthritis on a person's life.
The questionnaire comprises 12 numeric rating scale questions covering the following topics: pain, fatigue, skin problems, work/leisure activities, functional capacity, discomfort, sleep disturbance, coping with PsA, anxiety and fear and uncertainty, embarrassment and/or shame, social participation, depression.
Each question receives a score from 0 to 10.
For evaluation these are weighted by factors and then summarized.
The range of the final PsAID-score will be 0-10 where higher figures indicate worse status.
|
12 months
|
Quality of life and health/disability: HAQ-DI (Stanford Health Assessment Questionnaire Disability Index)
Time Frame: 12 months
|
The Stanford Health Assessment Questionnaire is based on a subject's self-assessment questionnaire for persons diagnosed with PsA.
The HAQ-DI assesses a patient's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.
There are 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities.
The stem of each item asks for the past week "Are you able to …" perform a particular task.
The patient's responses are made on a scale from zero (no disability) to three (completely disabled).
Each category contains at least two specific component questions.
|
12 months
|
Quality of life and health/disability: DLQI (Dermatology Life Quality Index)
Time Frame: 12 months
|
The DLQI is a score based on a subject's self-assessment questionnaire and used to measure the impact of the skin disease (psoriasis) on the quality of life of an affected person.
The questionnaire contains 10 questions covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment.
Each question refers to the impact of the skin disease on the patient's life over the previous week.
Each question receives a score from 0 to 3.
These are summarized to a final score with a possible range from 0 (meaning no impact on quality of life) to 30 (meaning maximum impact on quality of life).
|
12 months
|
Quality of life and health/disability: ASQoL (Ankylosing Spondylitis Quality of Life)
Time Frame: 12 months
|
The ASQoL is a scale based on a subject's self-assessment questionnaire to measure the impact of ankylosing spondylitis (AS) on the quality of life of a diseased person with emphasis on the ability of the person to fulfill his or her needs.
It consists of 18 items requesting a yes or no response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life.
The score range is 0-18.
High scores indicate worse quality of life.
|
12 months
|
Quality of life and health/Disability: SF-36 (Short Form Health)
Time Frame: 12 months
|
SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
These measures rely upon patient self-reporting and are now widely utilized for routine monitoring and assessment of care outcomes in adult patients.
The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.
The eight sections are: vitality, physical functioning, bodily pains, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
|
12 months
|
Pain (VAS)
Time Frame: 12 months
|
The subject will be asked to place a vertical line on a 100-mm scale on which the left-hand boundary represents "no pain," and the right-hand boundary represents "pain as severe as can be imagined."
The distance from the mark to the left-hand boundary will be recorded
|
12 months
|
Proportion of patients with loss of MDA within 12 months after baseline
Time Frame: 12 months
|
12 months
|
|
Proportion of patients with loss of MDA within 24 months after baseline
Time Frame: 24 months
|
24 months
|
|
Time to loss of MDA
Time Frame: 12 months
|
12 months
|
|
Time needed to restore MDA after readjustment of the DMARD therapy in subjects who lost MDA within the intervention period
Time Frame: 12 months
|
Time [days/weeks/month] to restore after lost MDA
|
12 months
|
Biomarker levels
Time Frame: 24 months
|
Serum cytokines, and molecular characterization of peripheral blood cells (e.g.
IL-8 (CXCL8), Calprotectin (S100A9/S100A9).
IL-22, lipocalin-2 (NGAL), beta defensin 2 [11], ILC, PBMC)
|
24 months
|
Intervention-related events within the observation period of 24 months after baseline
Time Frame: 24 months
|
Observed symptoms (AE) related to reduction (intervention) such as symptoms suspicious of worsening disease activity (flare)
|
24 months
|
AE (Adverse Event)
Time Frame: 12 months
|
Adverse Event
|
12 months
|
AR (Adverse Reaction)
Time Frame: 12 months
|
Adverse Reaction
|
12 months
|
SAE (Serious Adverse Event)
Time Frame: 12 months
|
Serious Adverse Event
|
12 months
|
SAR (Serious Adverse Reaction)
Time Frame: 12 months
|
Serious Adverse Reaction
|
12 months
|
SUSAR (Suspected Unexpected Serious Adverse Reaction)
Time Frame: 12 months
|
Suspected Unexpected Serious Adverse Reaction
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Skin Diseases, Papulosquamous
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Spondylarthritis
- Spondylitis
- Psoriasis
- Arthritis
- Arthritis, Psoriatic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Dermatologic Agents
- Protein Kinase Inhibitors
- Immune Checkpoint Inhibitors
- Reproductive Control Agents
- Phosphodiesterase Inhibitors
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Tumor Necrosis Factor Inhibitors
- Phosphodiesterase 4 Inhibitors
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Etanercept
- Adalimumab
- Methotrexate
- Infliximab
- Leflunomide
- Golimumab
- Abatacept
- Apremilast
- Certolizumab Pegol
- Ixekizumab
- Tofacitinib
- Sulfasalazine
- Ustekinumab
Other Study ID Numbers
- UKER-ATTRACTOR -01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriatic Arthritis
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, United Kingdom, Turkey, Belgium, France, Greece, Italy, Austria, Germany, Netherlands, Poland, Portugal, Romania, Lithuania, South Africa
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
-
Sun Pharmaceutical Industries LimitedCompleted
-
Bristol-Myers SquibbCompletedActive Psoriatic ArthritisSpain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
-
Pope Research CorporationAmgenWithdrawn
-
Sun Pharmaceutical Industries LimitedRecruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
-
Humanis Saglık Anonim SirketiCompletedPsoriasis and Psoriatic ArthritisIndia
Clinical Trials on Prednisolone
-
Children's Hospital of PhiladelphiaCompleted
-
Assiut UniversityCompleted
-
Hamamatsu UniversityCompletedChronic Disease | Eosinophilic PneumoniaJapan
-
Sparrow PharmaceuticalsRecruitingPolymyalgia RheumaticaGermany
-
IsalaCompletedChronic Obstructive Pulmonary DiseaseNetherlands
-
Institute of Child HealthUnknown
-
Postgraduate Institute of Medical Education and...Completed
-
Postgraduate Institute of Medical Education and...CompletedPost COVID-19 Diffuse Lung DiseaseIndia
-
Nanjing University School of MedicineCompleted
-
Cambridge University Hospitals NHS Foundation TrustUniversity Medical Center Groningen; Imperial College London; University Hospitals... and other collaboratorsTerminatedWegener's Granulomatosis | Microscopic PolyangiitisUnited Kingdom